Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine
Summary Background There are few data on the incidence of benign infections (upper respiratory tract infections, herpes lesions and viral warts) during exposure to azathioprine. Aims To determine the incidence of benign infections in IBD out‐patients receiving azathioprine (AZA+) and to look at th...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2009-05, Vol.29 (10), p.1106-1113 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1113 |
|---|---|
| container_issue | 10 |
| container_start_page | 1106 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 29 |
| creator | SEKSIK, P. COSNES, J. SOKOL, H. NION‐LARMURIER, I. GENDRE, J.‐P. BEAUGERIE, L. |
| description | Summary
Background There are few data on the incidence of benign infections (upper respiratory tract infections, herpes lesions and viral warts) during exposure to azathioprine.
Aims To determine the incidence of benign infections in IBD out‐patients receiving azathioprine (AZA+) and to look at the influence of leucocyte counts in the onset of these events.
Methods A total of 230 patients were included in a prospective cohort and observed during 207 patient‐years. Episodes of benign infections were collected and incidences of benign infections were compared between the AZA+ group and patients without AZA (AZA−).
Results The incidence of upper respiratory tract infections in the cohort was 2.1 ± 2.2 per observation‐year. There was no difference between the AZA+ (n = 169) and AZA− (n = 61) groups (2.2 ± 2.3 vs. 2.1 ± 2.1, P = 0.77). The incidence of herpes flares was significantly increased in the AZA+ group compared to the AZA− group (1.0 ± 2.6 vs. 0.2 ± 0.8 per year, P = 0.04). Similarly, there were significantly more patients with appearance or worsening viral warts in the AZA+ group (17.2% (AZA+) vs. 3.3% (AZA−), P = 0.004).
Conclusion This study suggests that the incidence of herpes flares and the appearance or worsening of viral warts are increased in IBD patients receiving AZA. |
| doi_str_mv | 10.1111/j.1365-2036.2009.03973.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00657487v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>746048064</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5133-49e402b5eea1ec2cc1b236bfd186bb2e5390c0dc39ce734c3e18a2bb2a034193</originalsourceid><addsrcrecordid>eNqNkc-O0zAQxi0EYsvCKyBfEEIiwX8SJzlwqFZAV6rESlR7tRxnQl0lTrCd7ZY34W1xSFU44otnPL_5xvaHEKYkpXF9OKSUizxhhIuUEVKlhFcFTx-foNWl8BStCBNVwkrKr9AL7w-EEFEQ9hxd0YoxllG6Qr9urTYNWA14aHEN1ny3eBpHcNiBH41TYXAnHJzSARvbgg5msP493ny7x8o2eHN3j_UUlIVh8v8QMZyzTvX9IlEPR-hwYzwoD3hUwYANPiqDCtDgowl7rH6qsDfD6IyFl-hZqzoPr877Ndp9_rS72STbr19ub9bbROeU8ySrICOszgEUBc20pjXjom4bWoq6ZpDzimjSaF5pKHimOdBSsVhRhGe04tfo3SK7V52Mg3vlTnJQRm7WWzmfxU_Li6wsHmhk3y7s6IYfE_gge-M1dN3yellkgmQlEVkky4XUbvDeQXuRpkTOFsqDnJ2Ss1NytlD-sVA-xtbX5yFT3UPzt_HsWQTenAHltepap6KF_sIxygtSCRG5jwt3NB2c_vsCcn23myP-GwfCueM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>746048064</pqid></control><display><type>article</type><title>Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>SEKSIK, P. ; COSNES, J. ; SOKOL, H. ; NION‐LARMURIER, I. ; GENDRE, J.‐P. ; BEAUGERIE, L.</creator><creatorcontrib>SEKSIK, P. ; COSNES, J. ; SOKOL, H. ; NION‐LARMURIER, I. ; GENDRE, J.‐P. ; BEAUGERIE, L.</creatorcontrib><description>Summary
Background There are few data on the incidence of benign infections (upper respiratory tract infections, herpes lesions and viral warts) during exposure to azathioprine.
Aims To determine the incidence of benign infections in IBD out‐patients receiving azathioprine (AZA+) and to look at the influence of leucocyte counts in the onset of these events.
Methods A total of 230 patients were included in a prospective cohort and observed during 207 patient‐years. Episodes of benign infections were collected and incidences of benign infections were compared between the AZA+ group and patients without AZA (AZA−).
Results The incidence of upper respiratory tract infections in the cohort was 2.1 ± 2.2 per observation‐year. There was no difference between the AZA+ (n = 169) and AZA− (n = 61) groups (2.2 ± 2.3 vs. 2.1 ± 2.1, P = 0.77). The incidence of herpes flares was significantly increased in the AZA+ group compared to the AZA− group (1.0 ± 2.6 vs. 0.2 ± 0.8 per year, P = 0.04). Similarly, there were significantly more patients with appearance or worsening viral warts in the AZA+ group (17.2% (AZA+) vs. 3.3% (AZA−), P = 0.004).
Conclusion This study suggests that the incidence of herpes flares and the appearance or worsening of viral warts are increased in IBD patients receiving AZA.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2009.03973.x</identifier><identifier>PMID: 19222411</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Azathioprine - adverse effects ; Biological and medical sciences ; Chemical Sciences ; Cohort Studies ; Digestive system ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Herpes Simplex - pathology ; Human papillomavirus ; Humans ; Immunosuppressive Agents - adverse effects ; Inflammatory Bowel Diseases - drug therapy ; Male ; Medical sciences ; Middle Aged ; Organic chemistry ; Other diseases. Semiology ; Papillomavirus Infections - chemically induced ; Pharmacology. Drug treatments ; Prospective Studies ; Respiratory Tract Infections - chemically induced ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Young Adult</subject><ispartof>Alimentary pharmacology & therapeutics, 2009-05, Vol.29 (10), p.1106-1113</ispartof><rights>2009 Blackwell Publishing Ltd</rights><rights>2009 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5133-49e402b5eea1ec2cc1b236bfd186bb2e5390c0dc39ce734c3e18a2bb2a034193</citedby><cites>FETCH-LOGICAL-c5133-49e402b5eea1ec2cc1b236bfd186bb2e5390c0dc39ce734c3e18a2bb2a034193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2036.2009.03973.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2036.2009.03973.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,315,781,785,886,1418,1434,27929,27930,45579,45580,46414,46838</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21370966$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19222411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00657487$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>SEKSIK, P.</creatorcontrib><creatorcontrib>COSNES, J.</creatorcontrib><creatorcontrib>SOKOL, H.</creatorcontrib><creatorcontrib>NION‐LARMURIER, I.</creatorcontrib><creatorcontrib>GENDRE, J.‐P.</creatorcontrib><creatorcontrib>BEAUGERIE, L.</creatorcontrib><title>Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background There are few data on the incidence of benign infections (upper respiratory tract infections, herpes lesions and viral warts) during exposure to azathioprine.
Aims To determine the incidence of benign infections in IBD out‐patients receiving azathioprine (AZA+) and to look at the influence of leucocyte counts in the onset of these events.
Methods A total of 230 patients were included in a prospective cohort and observed during 207 patient‐years. Episodes of benign infections were collected and incidences of benign infections were compared between the AZA+ group and patients without AZA (AZA−).
Results The incidence of upper respiratory tract infections in the cohort was 2.1 ± 2.2 per observation‐year. There was no difference between the AZA+ (n = 169) and AZA− (n = 61) groups (2.2 ± 2.3 vs. 2.1 ± 2.1, P = 0.77). The incidence of herpes flares was significantly increased in the AZA+ group compared to the AZA− group (1.0 ± 2.6 vs. 0.2 ± 0.8 per year, P = 0.04). Similarly, there were significantly more patients with appearance or worsening viral warts in the AZA+ group (17.2% (AZA+) vs. 3.3% (AZA−), P = 0.004).
Conclusion This study suggests that the incidence of herpes flares and the appearance or worsening of viral warts are increased in IBD patients receiving AZA.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Azathioprine - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Chemical Sciences</subject><subject>Cohort Studies</subject><subject>Digestive system</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Herpes Simplex - pathology</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Organic chemistry</subject><subject>Other diseases. Semiology</subject><subject>Papillomavirus Infections - chemically induced</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Respiratory Tract Infections - chemically induced</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Young Adult</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc-O0zAQxi0EYsvCKyBfEEIiwX8SJzlwqFZAV6rESlR7tRxnQl0lTrCd7ZY34W1xSFU44otnPL_5xvaHEKYkpXF9OKSUizxhhIuUEVKlhFcFTx-foNWl8BStCBNVwkrKr9AL7w-EEFEQ9hxd0YoxllG6Qr9urTYNWA14aHEN1ny3eBpHcNiBH41TYXAnHJzSARvbgg5msP493ny7x8o2eHN3j_UUlIVh8v8QMZyzTvX9IlEPR-hwYzwoD3hUwYANPiqDCtDgowl7rH6qsDfD6IyFl-hZqzoPr877Ndp9_rS72STbr19ub9bbROeU8ySrICOszgEUBc20pjXjom4bWoq6ZpDzimjSaF5pKHimOdBSsVhRhGe04tfo3SK7V52Mg3vlTnJQRm7WWzmfxU_Li6wsHmhk3y7s6IYfE_gge-M1dN3yellkgmQlEVkky4XUbvDeQXuRpkTOFsqDnJ2Ss1NytlD-sVA-xtbX5yFT3UPzt_HsWQTenAHltepap6KF_sIxygtSCRG5jwt3NB2c_vsCcn23myP-GwfCueM</recordid><startdate>20090515</startdate><enddate>20090515</enddate><creator>SEKSIK, P.</creator><creator>COSNES, J.</creator><creator>SOKOL, H.</creator><creator>NION‐LARMURIER, I.</creator><creator>GENDRE, J.‐P.</creator><creator>BEAUGERIE, L.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>1XC</scope></search><sort><creationdate>20090515</creationdate><title>Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine</title><author>SEKSIK, P. ; COSNES, J. ; SOKOL, H. ; NION‐LARMURIER, I. ; GENDRE, J.‐P. ; BEAUGERIE, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5133-49e402b5eea1ec2cc1b236bfd186bb2e5390c0dc39ce734c3e18a2bb2a034193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Azathioprine - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Chemical Sciences</topic><topic>Cohort Studies</topic><topic>Digestive system</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Herpes Simplex - pathology</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Organic chemistry</topic><topic>Other diseases. Semiology</topic><topic>Papillomavirus Infections - chemically induced</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Respiratory Tract Infections - chemically induced</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SEKSIK, P.</creatorcontrib><creatorcontrib>COSNES, J.</creatorcontrib><creatorcontrib>SOKOL, H.</creatorcontrib><creatorcontrib>NION‐LARMURIER, I.</creatorcontrib><creatorcontrib>GENDRE, J.‐P.</creatorcontrib><creatorcontrib>BEAUGERIE, L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SEKSIK, P.</au><au>COSNES, J.</au><au>SOKOL, H.</au><au>NION‐LARMURIER, I.</au><au>GENDRE, J.‐P.</au><au>BEAUGERIE, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2009-05-15</date><risdate>2009</risdate><volume>29</volume><issue>10</issue><spage>1106</spage><epage>1113</epage><pages>1106-1113</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background There are few data on the incidence of benign infections (upper respiratory tract infections, herpes lesions and viral warts) during exposure to azathioprine.
Aims To determine the incidence of benign infections in IBD out‐patients receiving azathioprine (AZA+) and to look at the influence of leucocyte counts in the onset of these events.
Methods A total of 230 patients were included in a prospective cohort and observed during 207 patient‐years. Episodes of benign infections were collected and incidences of benign infections were compared between the AZA+ group and patients without AZA (AZA−).
Results The incidence of upper respiratory tract infections in the cohort was 2.1 ± 2.2 per observation‐year. There was no difference between the AZA+ (n = 169) and AZA− (n = 61) groups (2.2 ± 2.3 vs. 2.1 ± 2.1, P = 0.77). The incidence of herpes flares was significantly increased in the AZA+ group compared to the AZA− group (1.0 ± 2.6 vs. 0.2 ± 0.8 per year, P = 0.04). Similarly, there were significantly more patients with appearance or worsening viral warts in the AZA+ group (17.2% (AZA+) vs. 3.3% (AZA−), P = 0.004).
Conclusion This study suggests that the incidence of herpes flares and the appearance or worsening of viral warts are increased in IBD patients receiving AZA.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19222411</pmid><doi>10.1111/j.1365-2036.2009.03973.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2009-05, Vol.29 (10), p.1106-1113 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00657487v1 |
| source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
| subjects | Adolescent Adult Aged Azathioprine - adverse effects Biological and medical sciences Chemical Sciences Cohort Studies Digestive system Female Gastroenterology. Liver. Pancreas. Abdomen Herpes Simplex - pathology Human papillomavirus Humans Immunosuppressive Agents - adverse effects Inflammatory Bowel Diseases - drug therapy Male Medical sciences Middle Aged Organic chemistry Other diseases. Semiology Papillomavirus Infections - chemically induced Pharmacology. Drug treatments Prospective Studies Respiratory Tract Infections - chemically induced Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Young Adult |
| title | Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T19%3A27%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20of%20benign%20upper%20respiratory%20tract%20infections,%20HSV%20and%20HPV%20cutaneous%20infections%20in%20inflammatory%20bowel%20disease%20patients%20treated%20with%20azathioprine&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=SEKSIK,%20P.&rft.date=2009-05-15&rft.volume=29&rft.issue=10&rft.spage=1106&rft.epage=1113&rft.pages=1106-1113&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2009.03973.x&rft_dat=%3Cproquest_hal_p%3E746048064%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=746048064&rft_id=info:pmid/19222411&rfr_iscdi=true |